The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

B-Cell Prolymphocytic Leukemia: Diagnosis and Management

Rare aggressive lymphoproliferative disorder with prolymphocyte morphology and challenging treatment

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is B-Cell Prolymphocytic Leukemia: Diagnosis and Management?

B-PLL is defined by prolymphocytes constituting more than 55 percent of peripheral blood lymphocytes with characteristic morphology and immunophenotype.

WHO classification recognizes B-PLL as distinct from chronic lymphocytic leukemia though some cases may represent transformation or progression.

Cytogenetic abnormalities frequently include 17p deletion (TP53), MYC rearrangements and complex karyotypes affecting prognosis and treatment.

Differential diagnosis from CLL with prolymphocytoid transformation, mantle cell lymphoma in leukemic phase and splenic marginal zone lymphoma is critical.

Comprehensive workup includes flow cytometry, FISH, cytogenetics, TP53 sequencing and bone marrow examination.

Symptoms

B symptoms with fever, night sweats and weight loss in many patients.
Marked splenomegaly often massive with abdominal discomfort, early satiety and pain.
Lymphadenopathy is less prominent compared with CLL, often minimal or absent.
Symptoms of cytopenias including fatigue from anemia, infections from neutropenia and bleeding from thrombocytopenia.
Marked lymphocytosis with white blood cell counts often exceeding 100×10⁹/L.

Risk Factors

Older age with median age at diagnosis approximately 65 to 70 years.
Male predominance with male to female ratio approximately 2:1.
Prior CLL with prolymphocytic transformation in subset of cases.
No clearly established environmental risk factors for de novo disease.
Genetic susceptibility with rare familial cases reported.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Marked unexplained lymphocytosis with prolymphocyte morphology requires hematology evaluation and comprehensive workup.
  • Massive splenomegaly with cytopenias warrants prompt specialty referral.
  • Patients with CLL showing transformation suggested by rapid clinical change need reassessment.
  • Treatment failure or relapse following initial therapy requires multidisciplinary case discussion.
  • Long-term hematologic follow-up is essential given aggressive disease behavior and treatment challenges.

Treatment Methods

01
BTK inhibitors including ibrutinib are emerging as preferred initial therapy with response in many patients.
02
Combination therapy with rituximab plus chemotherapy regimens for fit patients lacking TP53 abnormalities.
03
Venetoclax-based combinations show promise particularly in TP53-disrupted disease.
04
Allogeneic hematopoietic stem cell transplantation for younger fit patients with high-risk disease.
05
Comprehensive care including individualized treatment selection based on molecular profile and patient factors, supportive care for cytopenias, infection prophylaxis, clinical trial enrollment and ongoing monitoring optimize outcomes in this challenging rare disease.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.